1,590
Views
10
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: RADIATION THERAPY

RBE for proton radiation therapy – a Nordic view in the international perspective

, ORCID Icon, , &
Pages 1151-1156 | Received 09 Jul 2020, Accepted 16 Sep 2020, Published online: 01 Oct 2020

References

  • PTCOG. Facilities in operation [Internet]. Villigen (Switzerland): Particle Therapy Co-Operative Group; 2020 [cited 2020 June 30]. Available from: https://www.ptcog.ch/index.php/facilities-in-operation
  • PTCOG. Facilities under construction [Internet]. Villigen (Switzerland): Particle Therapy Co-Operative Group; 2020 [cited 2020 June 30]. Available from: https://www.ptcog.ch/index.php/facilities-under-construction
  • Suit H, DeLaney T, Goldberg S, et al. Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiother Oncol. 2010;95:3–22.
  • ICRU. Prescribing, recording, and reporting proton-beam therapy. Bethesda (MD): International Commission on Radiation Units and Measurements; 2007. (ICRU Report 78).
  • Dasu A, Toma-Dasu I. Impact of variable RBE on proton fractionation. Med Phys. 2013;40:011705.
  • Paganetti H. Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer. Phys Med Biol. 2014;59:R419–R472.
  • Hawkins RB. A microdosimetric-kinetic model of cell death from exposure to ionizing radiation of any LET, with experimental and clinical applications. Int J Radiat Biol. 1996;69:739–755.
  • Scholz M, Kellerer AM, Kraft-Weyrather W, et al. Computation of cell survival in heavy ion beams for therapy. The model and its approximation. Radiat Environ Biophys. 1997;36:59–66.
  • Antonovic L, Brahme A, Furusawa Y, et al. Radiobiological description of the LET dependence of the cell survival of oxic and anoxic cells irradiated by carbon ions. J Radiat Res. 2013;54:18–26.
  • Carabe-Fernandez A, Dale RG, Jones B. The incorporation of the concept of minimum RBE (RBEmin) into the linear-quadratic model and the potential for improved radiobiological analysis of high-LET treatments. Int J Radiat Biol. 2007;83(1):27–39.
  • Wedenberg M, Lind BK, Hardemark B. A model for the relative biological effectiveness of protons: the tissue specific parameter alpha/beta of photons is a predictor for the sensitivity to LET changes. Acta Oncol. 2013;52(3):580–588.
  • McNamara AL, Schuemann J, Paganetti H. A phenomenological relative biological effectiveness (RBE) model for proton therapy based on all published in vitro cell survival data. Phys Med Biol. 2015;60:8399–8416.
  • Rorvik E, Thornqvist S, Stokkevag CH, et al. A phenomenological biological dose model for proton therapy based on linear energy transfer spectra. Med Phys. 2017;44:2586–2594.
  • Wedenberg M, Toma-Dasu I. Disregarding RBE variation in treatment plan comparison may lead to bias in favor of proton plans. Med Phys. 2014;41:091706.
  • Ödén J, Toma-Dasu I, Eriksson K, et al. The influence of breathing motion and a variable relative biological effectiveness in proton therapy of left-sided breast cancer. Acta Oncol. 2017;56(11):1428–1436.
  • Pedersen J, Petersen JBB, Stokkevag CH, et al. Biological dose and complication probabilities for the rectum and bladder based on linear energy transfer distributions in spot scanning proton therapy of prostate cancer. Acta Oncol. 2017;56(11):1413–1419.
  • Tilly N, Johansson J, Isacsson U, et al. The influence of RBE variations in a clinical proton treatment plan for a hypopharynx cancer. Phys Med Biol. 2005;50(12):2765–2777.
  • Mohan R, Peeler CR, Guan F, et al. Radiobiological issues in proton therapy. Acta Oncol. 2017;56(11):1367–1373.
  • Willers H, Allen A, Grosshans D, et al. Toward a variable RBE for proton beam therapy. Radiother Oncol. 2018;128(1):68–75.
  • Paganetti H, Blakely E, Carabe-Fernandez A, et al. Report of the AAPM TG-256 on the relative biological effectiveness of proton beams in radiation therapy. Med Phys. 2019;46(3):e53–e78.
  • Gutierrez A, Rompokos V, Li K, et al. The impact of proton LET/RBE modeling and robustness analysis on base-of-skull and pediatric craniopharyngioma proton plans relative to VMAT. Acta Oncol. 2019;58(12):1765–1774.
  • Wang CC, McNamara AL, Shin J, et al. End-of-range radiobiological effect on rib fractures in patients receiving proton therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2020;107(3):449–454.
  • Kopp B, Jensen MF, Mein S, et al. FRoG: an independent dose and LETd prediction tool for proton therapy at ProBeam® facilities. Med Phys. 2020. DOI:10.1002/mp.14417
  • Haas-Kogan D, Indelicato D, Paganetti H, et al. National Cancer Institute workshop on proton therapy for children: considerations regarding brainstem injury. Int J Radiat Oncol Biol Phys. 2018;101:152–168.
  • Jones B. Towards achieving the full clinical potential of proton therapy by inclusion of LET and RBE models. Cancers. 2015;7(1):460–480.
  • Ödén J, Toma-Dasu I, Witt-Nyström P, et al. Spatial correlation of linear energy transfer and relative biological effectiveness with suspected treatment-related toxicities following proton therapy for intracranial tumors. Med Phys. 2020;47(2):342–351.
  • Unkelbach J, Botas P, Giantsoudi D, et al. Reoptimization of intensity modulated proton therapy plans based on linear energy transfer. Int J Radiat Oncol Biol Phys. 2016;96(5):1097–1106.
  • Fjaera LF, Li Z, Ytre-Hauge KS, et al. Linear energy transfer distributions in the brainstem depending on tumour location in intensity-modulated proton therapy of paediatric cancer. Acta Oncol. 2017;56(6):763–768.
  • Toussaint L, Indelicato DJ, Holgersen KS, et al. Towards proton arc therapy: physical and biologically equivalent doses with increasing number of beams in pediatric brain irradiation. Acta Oncol. 2019;58(10):1451–1456.
  • McMahon SJ, Paganetti H, Prise KM. LET-weighted doses effectively reduce biological variability in proton radiotherapy planning. Phys Med Biol. 2018;63(22):225009.
  • Ödén J, Eriksson K, Toma-Dasu I. Incorporation of relative biological effectiveness uncertainties into proton plan robustness evaluation. Acta Oncol. 2017;56(6):769–778.
  • Sanchez-Parcerisa D, Lopez-Aguirre M, Dolcet Llerena A, et al. MultiRBE: treatment planning for protons with selective radiobiological effectiveness. Med Phys. 2019;46(9):4276–4284.
  • Resch AF, Landry G, Kamp F, et al. Quantification of the uncertainties of a biological model and their impact on variable RBE proton treatment plan optimization. Phys Med. 2017;36:91–102.
  • Langendijk JA, Lambin P, De Ruysscher D, et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107(3):267–273.
  • Ödén J, Eriksson K, Toma-Dasu I. Inclusion of a variable RBE into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy. Med Phys. 2017;44(3):810–822.
  • Traneus E, Ödén J. Introducing proton track-end objectives in intensity modulated proton therapy optimization to reduce linear energy transfer and relative biological effectiveness in critical structures. Int J Radiat Oncol Biol Phys. 2019;103(3):747–757.
  • Fager M, Toma-Dasu I, Kirk M, et al. Linear energy transfer painting with proton therapy: a means of reducing radiation doses with equivalent clinical effectiveness. Int J Radiat Oncol Biol Phys. 2015;91(5):1057–1064.
  • Ödén J, Hahn C, Vestergaard A, et al. INSPIRE: A multi-centric study to harmonize linear energy transfer (LET) calculations for biological assessments of proton therapy plans. [Abstract] Joint AAPM/COMP Meeting 2020 WE-B-TRACK 3–3.
  • Nystrom H, Jensen MF, Nystrom PW. Treatment planning for proton therapy: what is needed in the next 10 years? Br J Radiol. 2020;93(1107):20190304.
  • Saini J, Maes D, Egan A, et al. Dosimetric evaluation of a commercial proton spot scanning Monte-Carlo dose algorithm: comparisons against measurements and simulations. Phys Med Biol. 2017;62(19):7659–7681.
  • Wagenaar D, Tran LT, Meijers A, et al. Validation of linear energy transfer computed in a Monte Carlo dose engine of a commercial treatment planning system. Phys Med Biol. 2020;65(2):025006.
  • Newpower M, Patel D, Bronk L, et al. Using the proton energy spectrum and microdosimetry to model proton relative biological effectiveness. Int J Radiat Oncol Biol Phys. 2019;104(2):316–324.
  • Bertolet A, Baratto‐Roldán A, Cortés‐Giraldo MA, et al. Segment‐averaged LET concept and analytical calculation from microdosimetric quantities in proton radiation therapy. Med Phys. 2019;46(9):4204–4214.
  • Bertolet A, Cortés‐Giraldo MA, Souris K, et al. Calculation of clinical dose distributions in proton therapy from microdosimetry. Med Phys. 2019;46(12):5816–5823.